How to buy Synthetic Biologics stock (SYN)

Synthetic Biologics is a biotechnology business based in the US. Synthetic Biologics shares (SYN) are listed on the NYSE and all prices are listed in US Dollars. Synthetic Biologics employs 16 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Synthetic Biologics stock

Buy Synthetic Biologics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Synthetic Biologics stock price (NYSE: SYN)

Use our graph to track the performance of SYN stocks over time.

Synthetic Biologics shares at a glance

• Key figures

Information last updated 2022-12-07.

52-week range	$0.00 - $0.00
50-day moving average more info button	$1.24
200-day moving average more info button	$2.05
Wall St. target price	$5.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.12

Is it a good time to buy Synthetic Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synthetic Biologics financials

Gross profit TTM	$0
Return on assets TTM	-13.92%
Return on equity TTM	-26.26%
Profit margin	0%
Book value	$3.89
Market Capitalization more info button	$16.2 million

TTM: trailing 12 months

Synthetic Biologics share dividends

We're not expecting Synthetic Biologics to pay a dividend over the next 12 months.

Have Synthetic Biologics's shares ever split?

Synthetic Biologics's shares were split on a 1:10 basis on 24 July 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synthetic Biologics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Synthetic Biologics shares which in turn could have impacted Synthetic Biologics's share price.

Synthetic Biologics share price volatility

Over the last 12 months, Synthetic Biologics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Synthetic Biologics's is 1.3887. This would suggest that Synthetic Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Synthetic Biologics overview

Synthetic Biologics, Inc. , a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.

Frequently asked questions

What percentage of Synthetic Biologics is owned by insiders or institutions?
Currently 1.98% of Synthetic Biologics shares are held by insiders and 8.084% by institutions. How many people work for Synthetic Biologics?
Latest data suggests 16 work at Synthetic Biologics. When does the fiscal year end for Synthetic Biologics?
Synthetic Biologics's fiscal year ends in December. Where is Synthetic Biologics based?
Synthetic Biologics's address is: 9605 Medical Center Drive, Rockville, MD, United States, 20850 What is Synthetic Biologics's ISIN number?
Synthetic Biologics's international securities identification number is: US87164U2015 What is Synthetic Biologics's CUSIP number?
Synthetic Biologics's Committee on Uniform Securities Identification Procedures number is: 724153101